EW - Edwards Lifesciences Corporation Stock Analysis

DATE	TYPE	RATIO
2020-06-01	Forward	3:1
2015-12-14	Forward	2:1
2010-05-28	Forward	2:1

DATE

TYPE

RATIO

2020-06-01

Forward

3:1

2015-12-14

Forward

2:1

2010-05-28

Forward

2:1

Latest News

BUSINESS WIRE · OCT 7, 2026

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.

READ ARTICLE

EARLIER COVERAGE

BUSINESS WIRE · OCT 5, 2026

Edwards Lifesciences to Host Investor Event in Conjunction With TCT

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.

READ ARTICLE

BUSINESS WIRE · OCT 1, 2026

Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.

READ ARTICLE

GURUFOCUS · SEP 30, 2026

Is EW Overvalued? DCF Says Worth $40

On September 30, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a mixed price performance recently, with a ye

READ ARTICLE